{
    "clinical_study": {
        "@rank": "119191", 
        "arm_group": {
            "arm_group_label": "VB-111", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, open label, dose escalating, Phase I/II study, measuring mainly the\n      safety and tolerability of the combination of intravenous administration of VB-111 and\n      paclitaxel in patients with platinum resistant ovarian cancer."
        }, 
        "brief_title": "A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant M\u00fcllerian Cancer", 
        "condition": "Platinum Resistant Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged > 18\n\n          -  Histologically confirmed epithelial ovarian, peritoneal, or fallopian tube cancer,\n             and uterine papillary serous carcinomas (UPSC), and gynecologic malignant mixed\n             m\u00fcllerian tumors (MMMTs).\n\n          -  Must have had prior platinum or platinum based therapy.\n\n          -  Eastern Cooperative Oncology Group (ECOG) status 0-1.\n\n          -  Platinum resistant or refractory disease within 6 months of completing or while\n             receiving a platinum and taxane containing regimen\n\n          -  Measurable disease\n\n          -  Adequate bone marrow and hematological function.\n\n          -  Must have recovered from acute toxicity from prior treatment\n\n          -  Prior treatment with an anti-angiogenic agent is not an exclusion criterion.\n\n          -  No prior GI perforation, or GI obstruction or involvement of the bowel on imaging\n\n          -  Known hypersensitivity to Cremophor EL. However, participants are eligible if they\n             have had a prior paclitaxel reaction, but subsequently tolerated the drug at\n             rechallenge.\n\n          -  No patients receiving other investigational therapy for the past 30 days before\n             dosing.\n\n        Exclusion Criteria:\n\n          -  More than 3 prior lines of chemotherapy for recurrent cancer.\n\n          -  History of other active malignancy, other than superficial basal cell and superficial\n             squamous cell, or carcinoma in situ of the cervix within last 2 years.\n\n          -  Life expectancy of less than 3 months\n\n          -  CTC Grade 1 or greater neuropathy (motor or sensory) from comorbidity other than\n             prior taxane exposure, such as diabetes.\n\n          -  Inadequately controlled hypertension or prior history of hypertensive crisis or\n             hypertensive encephalopathy.\n\n          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure.\n\n          -  History of myocardial infarction or unstable angina within 6 months prior to study\n             Day 1.\n\n          -  History of stroke or transient ischemic attack within 6 months prior to Day 1.\n\n          -  Known CNS disease, except for treated brain metastasis\n\n          -  Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or\n             recent peripheral arterial thrombosis) within 6 months prior to Day 1.\n\n          -  History of hemoptysis (1/2 teaspoon of bright red blood per episode) within 1 month\n             prior to Day 1.\n\n          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of\n             therapeutic anticoagulation)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01801215", 
            "nct_id": "NCT01711970", 
            "org_study_id": "VB-111-157", 
            "secondary_id": "11-418"
        }, 
        "intervention": {
            "arm_group_label": "VB-111", 
            "intervention_name": "Paclitaxel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "contact": {
                "last_name": "Richard Penson, MD", 
                "phone": "617-726-5867"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "Richard Penson, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant M\u00fcllerian Cancer", 
        "overall_contact": {
            "last_name": "Richard Penson, MD", 
            "phone": "617-726-5867"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Define toxicities of a limited number of doses of combination VB-111 and weekly paclitaxel spanning anticipated effective doses.", 
            "measure": "Define toxicities", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711970"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Vascular Biogenics Ltd. operating as VBL Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vascular Biogenics Ltd. operating as VBL Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}